Significant inverse associations of serum n-6 fatty acids with plasma plasminogen activator inhibitor-1

British Journal of Nutrition

Volumn 107, Issue 4, 2012, Pages 567-572

  Lee, Sunghee ^a   Curb, J David ^b,c,d   Kadowaki, Takashi ^b   Evans, Rhobert W ^a   Miura, Katsuyuki ^b   Takamiya, Tomoko ^a   Shin, Chol ^e   El Saed, Aiman ^a   Choo, Jina ^e   Fujiyoshi, Akira ^b   Otake, Teruo ^a   Kadowaki, Sayaka ^b   Seto, Todd ^c   Masaki, Kamal ^c   Edmundowicz, Daniel ^f   Ueshima, Hirotsugu ^b   Kuller, Lewis H ^a   Sekikawa, Akira ^a,b  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c UNIVERSITY OF HAWAII   (United States)

^d PACIFIC HEALTH RESEARCH INSTITUTE   (United States)

^e Korea University   (South Korea)

^f UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Fatty acids; Linoleic acid; Plasminogen activator inhibitor 1

Indexed keywords

ARACHIDONIC ACID; LINOLEIC ACID; OMEGA 6 FATTY ACID; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ARTICLE; CAUCASIAN; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ELECTRON TOMOGRAPHY; ETHNIC DIFFERENCE; FATTY ACID ANALYSIS; FATTY ACID BLOOD LEVEL; GAS LIQUID CHROMATOGRAPHY; HUMAN; JAPANESE; MALE; MEN'S HEALTH; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RISK ASSESSMENT; RISK FACTOR;

EID: 84856748913     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114511003199     Document Type: Article

References (37)

1. Ha H, Oh EY & Lee HB (2009) The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases. Nat Rev Nephrol 5, 203-211.
2. Senno SL & Pechet L (1999) Clinical implications of elevated PAI-1 revisited: Multiple arterial thrombosis in a patient with essential thrombocythemia and elevated plasminogen activator inhibitor-1 (PAI-1) levels: A case report and review of the literature. J Thromb Thrombolysis 8, 105-112. (Pubitemid 29410835)
3. Folsom AR, Aleksic N, Park E, et al. (2001) Prospective study of fibrinolytic factors and incident coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 1, 611-617. (Pubitemid 32323396)
4. Thogersen AM, Jansson JH, Boman K, et al. (1998) High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98, 2241-2247. (Pubitemid 28533841)
5. Oh K, Hu FB, Manson JE, et al. (2005) Dietary fat intake and risk of coronary heart disease in women: 20 years of follow-up of the nurses' health study. Am J Epidemiol 161, 672-679. (Pubitemid 40411095)
6. Harris WS, Poston WC & Haddock CK (2007) Tissue n-3 and n-6 fatty acids and risk for coronary heart disease events. Atherosclerosis 193, 1-10. (Pubitemid 46776717)
7. Laaksonen DE, Nyyssonen K, Niskanen L, et al. (2005) Prediction of cardiovascular mortality in middle-aged men by dietary and serum linoleic and polyunsaturated fatty acids. Arch Intern Med 165, 193-199.
8. Zhao WS, Zhai JJ, Wang YH, et al. (2009) Conjugated linoleic acid supplementation enhances antihypertensive effect of ramipril in Chinese patients with obesity-related hypertension. Am J Hypertens 22, 680-686.
9. Knapp HR (1997) Dietary fatty acids in human thrombosis and hemostasis. Am J Clin Nutr 65, Suppl. 5, 1687-1698S.
10. Laaksonen DE, Lakka TA, Lakka HM, et al. (2002) Serum fatty acid composition predicts development of impaired fasting glycaemia and diabetes in middle-aged men. Diabet Med 19, 456-464. (Pubitemid 34639155)
11. Calder PC (2009) Polyunsaturated fatty acids and inflammatory processes: New twists in an old tale. Biochimie 91, 791-795.
12. Nelson GJ, Kelley DS, Emken EA, et al. (1997) A human dietary arachidonic acid supplementation study conducted in a metabolic research unit: Rationale and design. Lipids 32, 415-420. (Pubitemid 27173069)
13. Harris WS, Mozaffarian D, Rimm E, et al. (2009) Omega-6 fatty acids and risk for cardiovascular disease: A science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention. Circulation 119, 902-907.
14. Willett WC (2007) The role of dietary n-6 fatty acids in the prevention of cardiovascular disease. J Cardiovasc Med (Hagerstown) 8, Suppl. 1, S42-S45. (Pubitemid 47429082)
15. Kohler HP & Grant PJ (2000) Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 342, 1792-1801. (Pubitemid 30390240)
16. Levenson J, Giral P, Razavian M, et al. (1995) Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. Arterioscler Thromb Vasc Biol 15, 1263-1268.
17. Sekikawa A, Ueshima H, Kadowaki T, et al. (2007) Less subclinical atherosclerosis in Japanese men in Japan than in White men in the United States in the post-World War II birth cohort. Am J Epidemiol 165, 617-624. (Pubitemid 46348375)
18. Kagan A (1996) The Honolulu Heart Program: An Epidemiological Study of Coronary Heart Disease and Stroke. New York: Harwood Academic Press.
19. Abbott RD, Ueshima H, Rodriguez BL, et al. (2007) Coronary artery calcification in Japanese men in Japan and Hawaii. Am J Epidemiol 166, 1280-1287. (Pubitemid 350129415)
20. Declerck PJ & Collen D (1990) Measurement of plasminogen activator inhibitor 1 (PAI-1) in plasma with various monoclonal antibody-based enzyme-linked immunosorbent assays. Thromb Res Suppl 10, 3-9. (Pubitemid 20091388)
21. Macy EM, Meilahn EN, Declerck PJ, et al. (1993) Sample preparation for plasma measurement of plasminogen activator inhibitor-1 antigen in large population studies. Arch Pathol Lab Med 117, 67-70. (Pubitemid 23027011)
22. Declerck PJ, Alessi MC, Verstreken M, et al. (1988) Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 71, 220-225. (Pubitemid 18050415)
23. Sekikawa A, Curb JD, Ueshima H, et al. (2008) Marinederived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men: A cross-sectional study. J Am Coll Cardiol 52, 417-424. (Pubitemid 352043837)
24. Fleischman AI, Justice D, Bierenbaum ML, et al. (1975) Beneficial effect of increased dietary linoleate upon in vivo platelet function in man. J Nutr 105, 1286-1290.
25. O'Brien JR, Etherington MD & Jamieson S (1976) Effect of a diet of polyunsaturated fats on some platelet-function tests. Lancet 2, 995-996.
26. Byberg L, Smedman A, Vessby B, et al. (2001) Plasminogen activator inhibitor-1 and relations to fatty acid composition in the diet and in serum cholesterol esters. Arterioscler Thromb Vasc Biol 21, 2086-2092. (Pubitemid 34219766)
27. Thijssen MA, Hornstra G & Mensink RP (2005) Stearic, oleic, and linoleic acids have comparable effects on markers of thrombotic tendency in healthy human subjects. J Nutr 135, 2805-2811. (Pubitemid 43156545)
28. Banfi C, Rise P, Mussoni L, et al. (1997) Linoleic acid enhances the secretion of plasminogen activator inhibitor type 1 by HepG2 cells. J Lipid Res 38, 860-869. (Pubitemid 27255195)
29. Ye P, He YL, Wang Q, et al. (2007) The alteration of plasminogen activator inhibitor-1 expression by linoleic acid and fenofibrate in HepG2 cells. Blood Coagul Fibrinolysis 18, 15-19. (Pubitemid 46006268)
30. Bates EJ, Ferrante A, Smithers L, et al. (1995) Effect of fatty acid structure on neutrophil adhesion, degranulation and damage to endothelial cells. Atherosclerosis 116, 247-259.
31. Sinha B, Stoll D, Weber PC, et al. (1991) Polyunsaturated fatty acids modulate synthesis of TNF-[alpha] and interleukin- 1[beta] by human MNC in vitro. Cytokine 3, 457-457.
32. Kusumoto A, Ishikura Y, Kawashima H, et al. (2007) Effects of arachidonate-enriched triacylglycerol supplementation on serum fatty acids and platelet aggregation in healthy male subjects with a fish diet. Br J Nutr 8, 626-635. (Pubitemid 47277259)
33. Nelson GJ, Schmidt PC, Bartolini G, et al. (1997) The effect of dietary arachidonic acid on platelet function, platelet fatty acid composition, and blood coagulation in humans. Lipids 2, 421-425. (Pubitemid 27173070)
34. Schmitz G & Ecker J.2008) The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res 7, 147-155.
35. Choo J, Ueshima H, Curb JD, et al. (2010) Serum n-6 fatty acids and lipoprotein subclasses in middle-aged men: The population-based cross-sectional ERA-JUMP study. Am J Clin Nutr 1, 1195-1203.
36. Nilsson L, Gafvels M, Musakka L, et al. (1999) VLDL activation of plasminogen activator inhibitor-1 (PAI-1) expression: Involvement of the VLDL receptor. J Lipid Res 40, 913-919. (Pubitemid 29220532)
37. Willett WC, Howe GR & Kushi LH (1997) Adjustment for total energy intake in epidemiologic studies. Am J Clin Nutr 65, 1220S-11228.